Search results for "Patients"

showing 10 items of 962 documents

Breakthrough pain in oncology: A longitudinal study

2010

Abstract Context Existing studies on breakthrough pain (BP) have reported different prevalence rates because of different settings, populations, and assessment methods. These studies have used cross-sectional designs, and the relationship of BP with analgesic treatment has not been evaluated. Objectives The aim of this study was to longitudinally assess BP in cancer patients admitted to oncology units. Methods A consecutive sample of patients admitted to oncology centers was selected. At admission (T0), three months after admission (T3), and six months after admission (T6), data on background pain and BP were recorded. BP was assessed in terms of its intensity, duration, number of episodes,…

Oncologybreakthrough pain; Cancer pain; epidemiology; oncology; Acute Disease; Aged; Analgesics; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasms; Pain; Severity of Illness Index; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)Malemedicine.medical_specialtyLongitudinal studyBreakthrough PainAnalgesicPrevalencePainContext (language use)Severity of Illness Indexlongitudinal study; breakthrough pain; cancer patientsInternal medicineNeoplasmsEpidemiologymedicineHumansLongitudinal StudiesStage (cooking)Cancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedAnalgesicsbusiness.industrylongitudinal studyMiddle Agedbreakthrough painTreatment OutcomeAnesthesiology and Pain MedicineoncologyAcute DiseaseepidemiologyFemaleNeurology (clinical)cancer patientsbusinessCancer pain
researchProduct

Safety and efficacy of the treatment with Nab-paclitaxel in mEtastatic bREast cancer In elDerly patiEnts: NEREIDE study

2017

Oncologymedicine.medical_specialty010405 organic chemistrybusiness.industrySettore MED/06 - Oncologia MedicabREast cancer In elDerly patiEntsHematology010402 general chemistrymedicine.disease01 natural sciencesMetastatic breast cancer0104 chemical sciencesBreast cancerOncologyInternal medicinemedicinebusinessNab-paclitaxel
researchProduct

Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment

2010

The importance of adoption of recommendations for ONJ prevention strategy will notably grow for zoledronic acid in the next future, in view of possible further enlargement of its indications (even with different timing and schedules) in breast cancer patients without bone metastases (such as in adjuvant and neo-adjuvant settings, and in hormonotherapy-induced osteopenia

Oncologymedicine.medical_specialtyBreast Neoplasmszoledronic acidBreast cancerSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineHumansBone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawbusiness.industryImidazolesOsteonecrosisGeneral Medicinemedicine.diseaseosteonecrosis jawsZoledronic acidJawbreast cancer patientsFemaleSurgerybusinessOsteonecrosis of the jawmedicine.drugThe Breast
researchProduct

P-42 Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies as treatment option in vulnerable older patients with metastatic colorec…

2021

Oncologymedicine.medical_specialtyChemotherapybiologybusiness.industryColorectal cancermedicine.medical_treatmentTreatment optionsRetrospective cohort studyHematologymedicine.diseaseReduced doseOncologyOlder patientsInternal medicinebiology.proteinMedicineAntibodybusinessAnnals of Oncology
researchProduct

TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study

2020

Background: TAS-102 is an oral monotherapy, combining trifluridine and tipiracil hydrochloride, indicated for the treatment of pretreated metastatic colorectal cancer (mCRC). The aim of this real-life study is to evaluate the efficacy and safety of TAS-102 in heavily pretreated elderly patients with mCRC whose disease has progressed with standard therapies. Methods: In this retrospective observational study, we enrolled 50 elderly patients >70 years of age (median age 78 years) with a diagnosis of mCRC who were previously treated or were not considered candidates for treatment with other available therapies. Patients aged >70 years with advanced colorectal cancer and with an ECOG perf…

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentTrifluridineECOG Performance StatusDiseasechemotherapyelderly patientstrifluridine/tipiracilQuality of lifeInternal medicinemedicinelonsurfOriginal ResearchPharmacologyChemotherapybusiness.industrymetastatic colorectal cancertrifluridine/ tipiracillcsh:RM1-950Retrospective cohort studyGeneral Medicinemedicine.diseaselcsh:Therapeutics. PharmacologyTolerabilityquality of lifetas-102Molecular Medicinebusinessmedicine.drugDrugs in Context
researchProduct

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

2015

Abstract Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future…

Oncologymedicine.medical_specialtyInternational CooperationImmunologyMEDLINEMedical OncologyBiochemistryMyeloproliferative DisordersSurveys and QuestionnairesInternal medicinehemic and lymphatic diseasesmedicineHumansResponse criteriaCell ProliferationClinical Trials as TopicMyeloproliferative DisordersAdult patientsSurrogate endpointbusiness.industryStandard treatmentMyelodysplastic syndromesfood and beveragesCell BiologyHematologymedicine.diseaseClinical trialPhenotypeTreatment OutcomeHematologic NeoplasmsMyelodysplastic SyndromesMutationPractice Guidelines as TopicDisease ProgressionPhysical therapybusinessAlgorithmsPerspectives
researchProduct

Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplem…

2017

To the Editor, In their recent article, Stopeck et al. [1] concluded that denosumab confirms its known safety profile even after longterm exposure, or after switching to it from zoledronic acid, and that osteonecrosis of jaws (ONJ) rates increased with increasing exposure to antiresorptives, consistent with previous reports. This is based on the open label extension phase of two phase 3 studies in patients with breast and prostate cancer with bone metastases who were randomized to receive denosumab or zoledronic acid (ZA) [2, 3]. The patients were offered open-label denosumab for up to an additional 2 years after the results of the primary analysis, favorable for denosumab on several aspect…

Oncologymedicine.medical_specialtyPopulationlaw.invention03 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerRandomized controlled triallawInternal medicineNeoplasmsmedicineHumanseducationLetter to the Editoreducation.field_of_studyBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosisCancer030206 dentistrymedicine.diseaseSurgeryDenosumabZoledronic acidOncology030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawDenosumabOncology osteonecrosis denosumab metastatic cancer patientsbusinessJaw Diseasesmedicine.drug
researchProduct

High flow nasal therapy in perioperative medicine: from operating room to general ward

2018

Abstract Background High flow nasal therapy (HFNT) is a technique in which humidified and heated gas is delivered to the airways through the nose via small nasal prongs at flows that are higher than the rates generally applied during conventional oxygen therapy. The delivered high flow rates combine mixtures of air and oxygen and enable different inspired oxygen fractions ranging from 0.21 to 1. HFNT is increasingly used in critically ill adult patients, especially hypoxemic patients in different clinical settings. Main body Noninvasive ventilation delivers positive pressure (end-expiratory and inspiratory pressures or continuous positive airway pressure) via different external interfaces. …

Operating Roomsmedicine.medical_specialtymedicine.medical_treatmentPositive pressureReviewAcute respiratory failurePerioperative CarePerioperative medicinelcsh:RD78.3-87.303 medical and health sciences0302 clinical medicineOxygen therapyAnesthesiologyPatients' RoomsIntubation IntratrachealmedicineHumansIntubationContinuous positive airway pressureAdministration IntranasalHigh flow nasal therapyNosePerioperative medicinebusiness.industryOxygen Inhalation TherapyHumidity030208 emergency & critical care medicineOxygenationAnesthesiology and Pain Medicinemedicine.anatomical_structure030228 respiratory systemlcsh:AnesthesiologyAnesthesiaNasal CavitybusinessNoninvasive ventilationBMC Anesthesiology
researchProduct

Quantification of rifampicin and rifabutin in plasma of tuberculosis patients by micellar liquid chromatography

2020

A Micellar Liquid Chromatographic method is described to determine Rifampicin and Rifabutin in plasma from Tuberculosis patients. Samples were diluted in mobile phase and then directly injected, avoiding long and tedious extraction steps. The analytes were resolved from the matrix without interferences from endogenous compounds using a mobile phase of sodium dodecyl sulfate 0.15 mol L-1–6%(v/v) 1-pentanol and phosphate buffer at pH 3, running at 1 mL min−1 through a C18 column at 25 °C. Detection was carried out by UV absorbance at 270 nm. Under these conditions, the final chromatographic analysis time was 22 min. The analytical methodology was validated following the FDA 2018 Bioanalytical…

OptimizationAnalyteBioanalysisRifabutinPatientsAntituberculosis02 engineering and technology01 natural sciencesAnalytical ChemistryMatrix (chemical analysis)Plasmachemistry.chemical_compoundMicellarmedicineSodium dodecyl sulfateSpectroscopyChromatography010401 analytical chemistryExtraction (chemistry)021001 nanoscience & nanotechnology0104 chemical scienceschemistryMicellar liquid chromatographyDrug0210 nano-technologyRifampicinmedicine.drugMicrochemical Journal
researchProduct

Transcutaneous electric nerve stimulation (TENS) in dentistry- A review.

2014

Transcutaneous electric nerve stimulation (TENS) is a non-pharmacological method which is widely used by medical and paramedical professionals for the management of acute and chronic pain in a variety of conditions. Similarly, it can be utilized for the management of pain during various dental procedures as well as pain due to various conditions affecting maxillofacial region. This review aims to provide an insight into clinical research evidence available for the analgesic and non analgesic uses of TENS in pediatric as well as adult patients related to the field of dentistry. Also, an attempt is made to briefly discuss history of therapeutic electricity, mechanism of action of TENS, compon…

Oral Medicine and PathologyAdult patientsbusiness.industryDental proceduresChronic painTranscutaneous electric nerve stimulationDentistryOdontologíaReview:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludUNESCO::CIENCIAS MÉDICASMedicinebusinessGeneral DentistryJournal of clinical and experimental dentistry
researchProduct